US10864189B2 - Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care - Google Patents

Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care Download PDF

Info

Publication number
US10864189B2
US10864189B2 US16/455,002 US201916455002A US10864189B2 US 10864189 B2 US10864189 B2 US 10864189B2 US 201916455002 A US201916455002 A US 201916455002A US 10864189 B2 US10864189 B2 US 10864189B2
Authority
US
United States
Prior art keywords
acid
skin
group
topical emulsion
dermatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
US16/455,002
Other versions
US20200000765A1 (en
Inventor
Jenna Borok
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US16/455,002 priority Critical patent/US10864189B2/en
Publication of US20200000765A1 publication Critical patent/US20200000765A1/en
Application granted granted Critical
Publication of US10864189B2 publication Critical patent/US10864189B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/347—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/38—Percompounds, e.g. peracids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
    • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
    • A61K8/87—Polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
    • A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/007—Preparations for dry skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Definitions

  • the present invention relates to compositions and methods for the prevention and treatment of skin disorders.
  • the skin is the largest organ of the body, with a surface area of 18 square feet.
  • the keratinocytes produce keratin, a protein that gives skin its strength and flexibility and waterproofs the skin surface. Collagen and elastic fibers in the dermis give strength to the skin.
  • the skin is continuously exposed to changes in the external environment, including oxidative insults, heat, cold, UV radiation, injury, and mechanical stresses.
  • the stratum corneum composed of terminally differentiated keratinocytes, constitutes the natural barrier that prevents loss of water and penetration of infectious agents, such as bacteria and viruses, and foreign particles. Keratin intermediate filaments provide the cells with mechanical resilience and protects them against physical stress. Disruption of the keratin scaffold leads to tissue and cell fragility in the skin and its appendages (hair, nail, glands), oral mucosa, and cornea, and exposes the skin to pathological conditions and diseases.
  • Dermatitis also known as eczema
  • eczema is an inflammation of the skin that is characterized by the presence of itchy, erythematous, vesicular, weeping, and crusting patches.
  • Inflammatory agents include bacteria, fungi, viruses, and autoimmune, allergic, hormonal and malignant inflammatory agents.
  • the most common skin diseases or disorders include eczema, psoriasis, dermatitis, itching dermatosis, rosacea, perioral dermatitis, acne, non-melanoma skin cancer and melanoma.
  • recurrent dermatitis conditions include pruritus, dryness and skin rashes, which may be accompanied by redness, skin swelling, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding.
  • Common forms of dermatitis include atopic dermatitis and xerotic eczema.
  • Sunlight is a major cause of skin aging. Symptoms of photoaging are wrinkles, pigmentation, decreased skin elasticity, irregular texture and dryness. While treatment with moisturizers and steroid creams may temporarily control skin disorder and aging symptoms by reducing inflammation and smoothing wrinkles, the relief is only temporary. There is no known cure for dermatitis.
  • compositions and methods for the prevention and treatment of skin disorders relate to compositions and methods for the prevention and treatment of skin disorders.
  • topical compositions and methods of treatment comprising the combined use of one or more cannabinoids, or use of an ingredient that works on the endocannabinoid system, such as but not limited to, Palmitoylethanolamide (PEA), polyolprepolymers and stem cell extract.
  • PDA Palmitoylethanolamide
  • stem cell extract stem cell extract
  • the present invention relates to the use of polyolprepolymers, stem cell medium extract and cannabinoids or compounds that act on endocannabinoid receptors for skin care.
  • One embodiment of the invention is a topical composition for treating skin that comprises a therapeutically effective amount of at least one cannabinoid or molecule that acts on endocannabinoid receptors (e.g., Palmitoylethanolamide (PEA)), and a therapeutically effective amount of a polyolprepolymer, stem cell extract and BV-OSC (tetrahexyldecy ascorbate).
  • PDA Palmitoylethanolamide
  • at least one cannabinoid and either one up to all three of polyolprepolymer, stem cell extract and BV-OSC (tetrahexyldecy ascorbate) may be the only active ingredients of the composition.
  • the cannabinoids are present in the topical composition in a concentration between 0.1 and 30% by weight of the composition.
  • the cannabinoids are one or more of a natural phytocannabinoid, an organic cannabinoid, an endocannabinoid, a cannabinoid analog, a cannabinoid derivative, a synthetic cannabinoid and a cannabinoid receptor agonist.
  • the polyolprepolymers include all compositions for facilitation permeation enhancement of the product into the skin outlined in U.S. Pat. No. 5,045,317, which is incorporated herein by reference in its entirety for all purposes.
  • the stem cell medium extract are any multi-potent cell derived from human or plant stem cells used as a source of regenerative medicine.
  • another active ingredient is Benzoyl Peroxide and all possible formulations of it.
  • the cannabinoid is hemp oil.
  • the cannabinoid is one or more of cannabigerolic acid (CBGA), cannabigerolic acid monomethylether (CBGAM), cannabigerol (CBG), cannabigerol monomethylether (CBGM), cannabigerovarinic acid (CBGVA), cannabigerovarin (CBGV), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromevarinic acid (CBCVA), cannabichromevarin (CBCV), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabidiol monomethylether (CBDM), cannabidiol-C 4 (CBD-C 4 ), cannabidivarinic acid (CBDVA), cannabidivarin (CBDV), cannabidiorcol (CBD-C 1 ), delta-9-tetrahydrocannabinolic acid A (THCA-A),
  • the cannabinoid is a cannabinoid receptor agonist.
  • the cannabinoid receptor agonist comprises one or more of a naphthoylindole, a naphthylmethylindole, a naphthoylpyrrole, a naphthylmethylindene, a phenylacetylindole, a cyclohexylphenol and a Palmitoylethanolamide (PEA).
  • PDA Palmitoylethanolamide
  • the benzoyl peroxide is present in the topical composition in a concentration between 0.1 and 10% by weight of the composition.
  • the topical composition may further comprise a stabilizer.
  • the stabilizer is selected from the group consisting of guar gum, xanthan gum cellulose hyaluronic acid, polyvinyl pyrrolidone (PVP), alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitisin, corn starch and flour, and is present in an amount from about 0.25% to about 30% (w/v).
  • the topical composition is in the form of an ointment, a cream, an emulsion, a lotion, a paste, an unguent, a gel or a sunscreen.
  • the carrier in the topical composition comprises hemp oil.
  • the topical composition further comprises one or more of a thickening agent, an antibiotic, an antiseptic agent, an antifungal, an antibacterial agent, an analgesic or an antiviral agent.
  • the topical composition may further comprises a UV absorbing agent in an amount between 0.1 and 5% by weight of the composition.
  • the invention provides a method of treating skin, treating a skin disorder, or improving a condition of the skin in a subject in need thereof comprising topically administering to the subject the topical composition of the invention as described above.
  • the skin disorder is one or more of atopic dermatitis or eczema, psoriasis, dermatitis, itching dermatosis, seborrheic dermatitis, rosacea, perioral dermatitis, acne, non-melanoma cancer or melanoma.
  • the subject presents a symptom which is one or more of pruritus, dryness, skin rash, redness, swelling of the skin, itching, crusting, flaking, blistering, cracking, oozing, or bleeding.
  • the dermatitis is atopic dermatitis, contact dermatitis, xerotic eczema, or seborrheic dermatitis.
  • the composition of the invention is topically administered to the subject in an amount between about 100 nmol to about 1 .mu.mol/cm 2 .
  • the subject is a mammal.
  • the mammal is a human.
  • the invention provides a method for treating or preventing pruritus, dryness of the skin, skin rash, redness, swelling of the skin, itching, crusting, flaking, blistering, cracking, oozing, bleeding or blistering of the skin in a subject in need thereof, that comprises topically administering to the subject the composition of the invention.
  • the subject has one or more of eczema, psoriasis, dermatitis, itching dermatosis, rosacea, perioral dermatitis, acne, non-melanoma cancer or melanoma.
  • the dermatitis is atopic dermatitis, contact dermatitis, xerotic eczema, or seborrheic dermatitis.
  • the composition of the invention is topically administered to the subject in an amount between about 100 nmol to about 1 .mu.mol/cm 2 .
  • the subject is a mammal. In a preferred aspect of the invention, the mammal is a human.
  • FIG. 1 of US 2018/0021241A1 which is incorporated herein by reference in its entirety for all purposes, illustrates the chemical structure of some cannabinoids for use according to the invention.
  • Cannabinoids are terpenophenolic compounds found in Cannabis sativa, an annual plant belonging to the Cannabaceae family. The plant contains more than 400 chemicals and approximately 80 cannabinoids. The latter accumulate mainly in the glandular trichomes. Natural phytocannabinoids occur in the free acid forms within plant tissue.
  • the psychoactive cannabinoids tetrahydrocannbinol (THC), cannabidiol (CBD), cannabichromene (CBC) and cannabigerol (CBG) exist in their corresponding carboxylic acid forms THCA, CBDA, CBCA and CBGA within plant tissue and are converted to their active forms via non-enzymatic decarboxylation that occurs upon the drying of the plant tissue, or during storage or smoking.
  • THC tetrahydrocannabinol
  • Cannabidiol an isomer of THC, is a potent antioxidant and anti-inflammatory compound known to provide protection against acute and chronic neurodegeneration, and relief from chronic pain, inflammation, migraines, arthritis, spasms, epilepsy, and the like.
  • Cannabigerol which is found in high concentrations in hemp, acts as a high affinity .alpha 2 -adrenergic receptor agonist, moderate affinity 5-HT 1 A receptor antagonist and low affinity CB 1 receptor antagonist, and thus may have anti-depressant activity.
  • Cannabichromene CBC
  • THCV Tetrahydrocannabivarin
  • cannabinoids in topical compositions is limited by the fact that cannabinoids, because of their hydrophobic nature, must be dissolved in organic solvents that may irritate the skin.
  • Polyolprepolymers are polyalkylene glycol-based polyurethane polymers that readily deposit on and within the stratum corneum forming a reservoir rather than migrating further into the skin.
  • the polyolprepolymers are present in the topical composition in a concentration between 0.1 and 30% by weight of the total composition.
  • the polyolprepolymers are present in the topical composition in a concentration between 0.1 and 25%, between 0.1 and 20%, between 0.1 and 15%, between 0.1 and 10%, or between 0.1 and 5% by weight of the total composition. This increases the efficacy of skin care formulations. This includes but is not limited to polyolprepolymer-2, polyolprepolymer-14 and polyolprepolymer-15, outlined in U.S. Pat. No. 5,045,317.
  • Alpha and beta hydroxy acids are chemical exfoliants.
  • Alpha hydroxy acids are carboxylic acids characterized by the presence of one hydroxyl group attached to the .alpha.-position of the carboxyl group, known for their beneficial exfoliating properties and for inducing skin proliferation and new cell growth.
  • Exemplary alpha-hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, citric acid and tartaric acid.
  • Alpha-hydroxy acids are different from beta-hydroxy acids, such as .beta.-hydroxybutanoic acid, which are carboxylic acids characterized by having one hydroxyl group attached to the .beta.-position of the carboxyl group.
  • compositions containing polyolprepolymers, BV-OSC and stem cell extract in combination with one or more cannabinoids provide a number of advantages not found when either active agent is used by itself, including reduced skin irritation and fast healing of any skin condition that is enhanced by inflammation including, but not limited to, acne, aging spots, scar formation, eczema and wrinkles.
  • the cannabinoids of the inventive compositions modulate the cannabinoid receptors CB 1 R and CB 2 R located in the skin and involved in the attenuation of pain and contact allergic reaction, and thus stimulate the proliferation, growth and differentiation of keratinocytes in the skin as well as their immune competence and/or tolerance.
  • the combination of the cannabinoids with polyolprepolymers results in an unexpected synergic anti-inflammatory effect due to the anti-inflammatory properties of the cannabinoids, and contributes to the total wellness of the skin.
  • the compositions containing a combination of one or more polyolprepolymers and one or more cannabinoids according to the invention provide greater skin improvement effects than the same compositions comprising either alone.
  • One embodiment of the invention is a topical composition for treating skin that comprises a therapeutically effective amount of at least one cannabinoid or molecule that acts on endocannabinoid receptors (e.g., Palmitoylethanolamide (PEA)), and a therapeutically effective amount of a polyolprepolymer, stem cell extract and BV-OSC (tetrahexyldecy ascorbate).
  • PDA Palmitoylethanolamide
  • BV-OSC tetrahexyldecy ascorbate
  • the stem cell extract is present in the topical composition in a concentration between 0.1 and 30% by weight of the composition.
  • the stem cell extract is present in the topical composition in a concentration between 0.1 and 25%, between 0.1 and 20%, between 0.1 and 15%, between 0.1 and 10%, or between 0.1 and 5%, by weight of the total composition.
  • the BV-OSC is present in the topical composition in a concentration between 0.1 and 30% by weight of the composition. In other embodiments of the invention, the BV-OSC is present in the topical composition in a concentration between 0.1 and 25%, between 0.1 and 20%, between 0.1 and 15%, between 0.1 and 10%, or between 0.1 and 5%, by weight of the total composition.
  • cannabinoid and “cannabinoids” include, but are not limited to, natural phytocannabinoids, organic cannabinoids, endocannabinoids, cannabinoid analogs, cannabinoid derivatives, synthetic cannabinoids and cannabinoid receptor agonists.
  • organic cannabinoids examples include, but are not limited to, hemp oil.
  • cannabinoids, cannabinoid analogs and cannabinoid derivatives include, but are not limited to, cannabigerolic acid (CBGA), cannabigerolic acid monomethylether (CBGAM), cannabigerol (CBG), cannabigerol monomethylether (CBGM), cannabigerovarinic acid (CBGVA), cannabigerovarin (CBGV), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromevarinic acid (CBCVA), cannabichromevarin (CBCV), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabidiol monomethylether (CBDM), cannabidiol-C 4 (CBD-C 4 ), cannabidivarinic acid (CBDVA), cannabidivarin (CBDV), cannabidiorcol (CBD-C 1 ), delta-9-tetrahydrocanna
  • Cannabinoid receptor agonists as used herein may include natural and synthetic compounds that are structurally related to natural cannabinoids, and natural and synthetic compounds that are not structurally related to natural cannabinoids, all of which interact with at least one of the cannabinoid receptors.
  • Cannabinoid receptor agonists that can be used according to the invention exert the same function as natural cannabinoids and share one or more common features with natural cannabinoids.
  • cannabinoid receptor agonists that are not structurally related to natural cannabinoids are lipid soluble and non-polar, consist of 22 to 26 carbon atoms and have a side-chain comprising more than four and up to nine saturated carbon atoms.
  • Non-limiting examples of cannabinoid receptor agonists that are not structurally related to natural cannabinoids include naphthoylindoles, naphthylmethylindoles, naphthoylpyrroles, naphthylmethylindenes, phenylacetylindoles, such as benzoylindoles, cyclohexylphenols, and Palmitoylethanolamide (PEA).
  • PDA Palmitoylethanolamide
  • Exemplary cannabinoid receptor agonists are well known in the art and include, but are not limited to, compounds of the molecular formula C 21 H 30 O 2 ; the molecular formula C 25 H 38 O 3 ; the molecular formula C 21 H 34 O 2 ; the molecular formula C 24 H 23 NO; the molecular formula C 22 H 25 NO 2 ; and the like.
  • the present invention provides a topical composition and methods for the treatment of a skin disorder or rejuvenation of the skin that comprise administering a topical composition, wherein the topical composition comprises a therapeutically effective amount of at least one cannabinoid and a therapeutically effective amount of at least one polyolprepolymers in a pharmaceutically acceptable carrier.
  • the carrier is an oil, cream or ointment.
  • the cannabinoids are present in the topical composition in a concentration between 0.1 and 30% by weight of the composition. In other embodiments of the invention, the cannabinoids are present in the topical composition in a concentration between 0.1 and 25%, between 0.1 and 20%, between 0.1 and 15%, between 0.1 and 10%, or between 0.1 and 5%, by weight of the total composition.
  • the cannabinoids are one or more of tetrahydrocannbinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV), analogs thereof, derivatives thereof, organic and synthetic cannabinoids and cannabinoid receptor agonists as described above.
  • THC tetrahydrocannbinol
  • CBD cannabidiol
  • CBG cannabigerol
  • CBC cannabichromene
  • THCV tetrahydrocannabivarin
  • the cannabinoids in the topical composition comprise one or more of a natural phytocannabinoid, an organic cannabinoid, an endocannabinoid, a cannabinoid analog, a cannabinoid derivative, a synthetic cannabinoid and a cannabinoid receptor agonist.
  • the cannabinoid receptor agonist may comprise one or more of a naphthoylindole, a naphthylmethylindole, a naphthoylpyrrole, a naphthylmethylindene, a phenylacetylindole, a cyclohexylphenol, and a Palmitoylethanolamide (PEA).
  • hydroxy acid includes, but is not limited to, alpha-hydroxy acid and beta-hydroxy acid.
  • the hydroxy acids are present in the topical composition in a concentration between 0.1 and 10% by weight of the composition.
  • Alpha hydroxy acids that may be used according to the invention comprise, but are not limited to, organic carboxylic acids in which one hydroxyl group is attached to the alpha carbon of the acids.
  • alpha hydroxy acids may be represented by the formula (Ra) (Rb) C (OH) COOH, wherein Ra and Rb are each H, F, Cl, Br, alkyl, aralkyl or aryl group of saturated or unsaturated, isomeric or non-isomeric, straight or branched chain or cyclic form, having 1 to 25 carbon atoms. Ra and Rb may also carry an OH, CHO, COOH or alkoxy group having 1 to 9 carbon atoms.
  • the hydroxy acids may be present in the topical composition as a free acid or in lactone form, or in a salt form with an organic base or an inorganic alkali.
  • the hydroxy adds may also exist as stereoisomers as D, L, and DL forms when Ra and Rb are not identical.
  • Typical alkyl, aralkyl and aryl groups for Ra and Rb include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, lauryl, stearyl, benzyl and phenyl.
  • Alpha hydroxy acids include (1) alkyl alpha hydroxyacids; (2) aralkyl and aryl alpha hydroxyacids; (3) polyhydroxy alpha hydroxyacids; and (4) polycarboxylic alpha hydroxyacids.
  • Alkyl alpha hydroxy acids include, but are not limited to, 2-hydroxyethanoic acid (glycolic acid, hydroxyacetic acid) (H) (H) c (OH) COOH; 2-hydroxypropanoic acid (lactic acid) (CH 3 ) (s) C (OH) COOH; 2-methyl 2-hydroxypropanoic acid (methyllactic acid) (CH 3 ) (CH 3 ) C (OH) COOH; 2-hydroxybutanoic acid (C 2 H 5 ) (H) C (OH) COOH, 2-hydroxypentanoic acid (C 3 H 7 ) (H) C (OH) COOH; 2-hydroxyhexanoic acid (C 4 H 9 ) (H) C (OH) COOH; 2-hydroxyheptanoic acid (C 5 H 11 (H) C (OH) COOH; 2-hydroxyoctanoic acid (C 6 H 13 ) (H) C (OH) COOH; 2-hydroxynonanoic acid (C 7 H 15 ) (H) C (OH) COOH
  • Aralkyl and aryl alpha hydroxy acids include, but are not limited to, 2-phenyl 2-hydroxyethanoic acid (mandelic acid) (C 6 H 5 ) (H) C (OH) COOH; 2,2-diphenyl 2-hydroxyethanoic acid (benzylic acid) (C 6 H 5 ) (C 6 H 5 ) C (OH) COOH; 3-pphenyl 2-hydroxypropanoic acid (phenyllactic acid) (C 6 H 5 CH 2 ) (H) C (OH) COOH; 2-pphenyl 2-methyl 2-hydroxyethanoic acid (atrolactic acid) (C 6 H 5 ) (CH 3 ) C (OH) COOH; 2-(4′-hydroxyphenyl)2-hydroxyethanoic acid (4-hydroxymandelic acid) (HO ⁇ C 6 H 4 ) (H) C (OH) COOH; 2-(4′-chlorophenyl) 2-hydroxyethanoic acid (4-chloromandelic acid) (Cl ⁇ C 6 H 4
  • Polyhydroxy alpha hydroxy acids include, but are not limited to, 2,3-dihydroxypropanoic acid (glyceiic acid) (HOCH 2 ) (H) C (OH) COOH; 2,3,4-trihydroxybutanoic acid (isomers; erythronic acid, threonic acid) HOCH 2 (HO)CH 2 (H) C (OH) COOH; 2,3,4,5-tetrahydroxypentanoic acid (isomers; ribonic acid, arabinoic acid, xylonic acid, lyxonic acid) HOCH 2 (HO) CH 2 (HO) CH 2 (H) C (OH) COOH; 2,3,4,5,6-pentahydroxyhexanoic acid (Isomers; allonic acid, altronic acid, gluconic acid, mannoic acid, gulonic acid, idonic acid, galactonic acid, talonic acid) HOCH 2 (HO)CH 2 (HO)CH 2 (HO)CH 2 (H) C (OH) COOH;
  • Polycarboxylic alpha hydroxy acids include, but are not limited to, 2-hydroxypropane-1,3-dioic acid (tartronic acid) HOOC (H) C (OH) COOH; 2hydroxybutane-1,4-dioic acid (malic acid) HOOC CH 2 (H) C (OH) COOH; 2,3-dihydroxybutane-1,4-dioic acid (tartaric acid) HOOC (HO)CH (Hi) C (OH) COOH; 2-hydroxy-2-carboxypentane-1,5-dioic acid (citric acid) HOOC CH 2 C (OH) (COOH) CH 2 COOH; 2,3,4,5-tetrahydroxyhexane-1,6-dioic acid (isomers; saccharic acid, mucic acid etc.) HOOC (CHOH) 4 COOH.
  • Lactone forms include, but are not limited to, gluconolactone, galactonolactone, glucuronolactone, galacturonolactone, gulonolactone, ribonolactone, saccharic acid lactone, pantoyllactone, glucoheptonolactone, mannonolactone, and galactoheptonolactone.
  • the alpha hydroxy acid is lactic acid, citric acid, glycolic acid, mandelic acid, benzylic acid, malic acid, tartaric acid, gluconolactone, galactonolactone, glucuronolactone, galacturonolactone, gulonolactone, ribonolactone, saccharic acid lactone, pantoyllactone, glucoheptonolactone, mannonolactone, or galactoheptonolactone.
  • the beta-hydroxy acid is salicylic acid.
  • the polyolprepolymers is PP-2, PP-14, or PP-15.
  • benzoyl peroxide is present from 0.1% up to 10% by weight of the total composition.
  • the topical composition may further comprise a stabilizer.
  • the stabilizer is selected from the group consisting of guar gum, xanthan gum cellulose hyaluronic acid, polyvinyl pyrrolidone (PVP), alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitisin, corn starch and flour, and is present in an amount from about 0.25% to about 30% (w/v).
  • the topical composition is in the form of an ointment, a cream, an emulsion, a lotion, a paste, an unguent, a gel or a sunscreen.
  • the carrier in the topical composition comprises hemp oil.
  • Creams according to the inventions include water-in-oil or oil-in-water emulsions and may further comprise a cleansing agent, an emollient and an aromatic chemical compound.
  • Ointments and unguents according to the invention optionally contain oil and water in a ratio from 2:1 to 7:1, and may further comprise a wax, alcohols and petroleum-based mollifying agents.
  • Gels according to the invention optionally contain a vegetable oil up to 5% by weight of the total composition, water and a thickening agent.
  • the thickening agent is a natural polysaccharide, such as xanthan gum, carrageen, an alginate or cellulose gum.
  • Pastes according to the invention may optionally contain aloe gel and beeswax.
  • Lotions according to the invention include oil-in-water or water-in-oil emulsions and may comprise cetyl alcohol, an emulsifier, a fragrance, glycerol, petroleum jelly, a dye, one or more preservatives and a stabilizing agent.
  • a sunscreen composition according to the invention may further comprise a UV absorbing or barrier agent in an amount between 0.1 and 10% by weight of the composition.
  • UV-absorbing compounds include, but are not limited to, benzone compounds, glyceryl PABA, roxadimate, octocrylene, octyl methoxycinnamate, ethoxyethyl p-methoxycinnamate, homomenthyl salicylate, ethylhexyl salicylate, trolamine salicylate, ecamsule, ensulizole, bemotrizinol and bisoctrizole.
  • Exemplary UV-barrier compounds include but are not limited to, zinc oxide and titanium dioxide.
  • the topical compositions of the invention may further comprise one or more active agents, such as an antibiotic, an antiseptic agent, an antifungal, an antibacterial agent, an analgesic or an antiviral agent.
  • the topical compositions of the invention may further comprise anesthetics, anti-cancer agents, antiacne agents, humectants, such as cationic, ionic and non-ionic surfactant, moisturizers, antipruritic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, antiaging and anti-wrinkle agents, skin lightening agents, depigmenting agents and vitamins.
  • antibiotics include, but are not limited to, ampicillin, bacampicillin, carbenicillin indanyl, mezlocillin, piperacillin, ticarcillin, amoxicillin-clavulanic acid, ampicillin-sulbactam, benzylpenicillin, cloxacillin, dicloxacillin, methicillin, oxacillin, penicillin G, penicillin V, piperacillin tazobactam, ticarcillin clavulanic acid, nafcillin, procaine penicillin, cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin, cephradine, cefaclor, cefamandol, cefonicid, cefotetan, cefoxitin, cefprozil, ceftmetazole, cefuroxime, loracarbef cefdinir, ceftibuten, cefoperazone, cefixime, cefo
  • Antiseptic compounds include, but are not limited to, iodine, manuka honey, octenidine dihydrochloride, phenol, polyhexanide, sodium chloride, sodium hypochlorite, calcium hypochlorite, sodium bicarbonate, methyl paraben, benzoyl peroxide and sodium dehydroacetate.
  • the amount of the antiseptic compound in the topical formulation is from 0.01 to 5% by weight of the total composition.
  • Antifungal agents include, but are not limited to, amphotericin B, candicidin, filipin, hamycin, natamycin, nystatin, rimocidin, bifonazole, butoconazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, luliconazole, miconazole, omoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, albaconazole, fluconazole, isavuconazole, itraconazole, posaconazole, ravuconazole, terconazole, voriconazole, abafungin, amorolfin, butenafine, naftifine, terbinafine, anidulafungin, caspofungin, micafungin, benzoic acid, ciclopirox, flucytosine, gris
  • Analgesic agents include, but are not limited to, methyl salicylate, codeine, morphine, methadone, pethidine, buprenorphine, hydromorphine, levorphanol, oxycodone, fentanyl, and a non-steroidal anti-inflammatory drug.
  • the amount of the analgesic agent in the topical formulation is from 0.01 to 5% by weight of the total composition.
  • Anti-viral agents include, but are not limited to, acyclovir, famciclovir, penciclovir, valacyclovir, trifluridine, docosanol, amantadine, rimantadine, oseltamivir, and zanamivir.
  • the amount of the anti-viral agent in the topical formulation is from 0.01 to 5% by weight of the total composition.
  • the topical composition of the invention may further comprise a stabilizer selected from the group consisting of guar gum, xanthan gum cellulose hyaluronic acid, polyvinyl pyrrolidone (PVP), alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitisin, corn starch and flour, in an amount from about 0.25% to about 2% (w/v).
  • a stabilizer selected from the group consisting of guar gum, xanthan gum cellulose hyaluronic acid, polyvinyl pyrrolidone (PVP), alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitisin, corn starch and flour, in an amount from about 0.25% to about 2% (w/v).
  • the composition for topical application to the skin comprises a therapeutically effective amount of at least one cannabinoid, a therapeutically effective amount of polyolprepolymers.
  • the cannabinoids according to the invention may be obtained as an extract from a cannabis plant for medical use, such as Cannabis sativa and Cannabis indica, by extracting the trichomes of the plants in a solvent and heating the mixture to evaporate the solvent.
  • extraction technologies include, but are not limited to, CO 2 extraction and microwave extraction.
  • the cannabinoids according to the invention may also be obtained as an extract from a cannabis transgenic plant that overexpresses one or more particular cannabinoids or that does not express or under-expresses one or more particular cannabinoids.
  • Synthetic cannabinoids may be prepared according to the technologies known to those skilled in the art.
  • endogenous nucleic acid sequences may be extracted from a cannabis plant and used to produce cannabinoids by recombinant technology.
  • the topical compositions of the invention may be prepared by dissolving the dry extracts of cannabinoids in an oil, and by adding the cannabinoid solution to a composition containing the hydroxy acids.
  • the hydroxy acid composition may be an alcohol solution in which the hydroxy acids are dissolved, or the hydroxy acids may be dissolved in an alcohol-free solution.
  • the hydroxy acids are dissolved in a composition comprising hemp oil or one or more cannabinoid, analogs thereof, derivatives thereof, organic and synthetic cannabinoids and cannabinoid receptor agonists as described above, wherein the one or more cannabinoids, analogs thereof, derivatives thereof, organic and synthetic cannabinoids and cannabinoid receptor agonists are dissolved in an oil.
  • the oil is a vegetable oil. Even more preferably the vegetable oil is hemp oil.
  • the invention provides a method to treat a skin disorder or rejuvenate the skin in a subject in need thereof, that comprises topically administering to the subject the topical composition of the invention as described above.
  • the skin disorder may be one or more of eczema, psoriasis, dermatitis, itching dermatosis, rosacea, perioral dermatitis, acne, non-melanoma cancer or melanoma.
  • the subject may present the first signs of irritation, or presents a severe symptom which is one or more of pruritus, dryness, skin rash, redness, swelling of the skin, itching, crusting, flaking, blistering, cracking, oozing, and bleeding.
  • the dermatitis may be atopic dermatitis, contact dermatitis, xerotic eczema, or seborrheic dermatitis.
  • the composition of the invention is topically administered to the subject in an amount between about 100 nmol to about 1 .mu.mol/cm 2 .
  • the subject is a mammal.
  • the mammal is a human.
  • the invention provides a method for treating or preventing pruritus, dryness of the skin, skin rash, redness, swelling of the skin, itching, crusting, flaking, blistering, cracking, oozing, bleeding or blistering of the skin in a subject in need thereof, that comprises topically administering to the subject the composition of the invention.
  • the subject may be disease-free or may be suspected of having or have one or more skin conditions, such as eczema, psoriasis, dermatitis, itching dermatosis, rosacea, perioral dermatitis, acne, non-melanoma cancer or melanoma.
  • the dermatitis may be atopic dermatitis, contact dermatitis, xerotic eczema, or seborrheic dermatitis.
  • the composition of the invention is topically administered to the subject in an amount between about 100 nmol to about 1 .mu.mol/cm 2 .
  • the subject is a mammal.
  • the mammal is a human.
  • 30 subjects with severe dermatitis are divided into two groups, 5 subjects per group. The subjects are instructed to topically apply a cream two times daily for two weeks. Group one is treated for two weeks with a cream containing hydroxyl acids, polyolprepolymer, stem cell extract and vehicle. Group two is treated for two weeks with a cream containing the hydroxyl acids, polyolprepolymer, stem cell extract, vehicle and cannabinoids. The effects of the different treatments are evaluated after two weeks.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Emergency Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Botany (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to compositions and methods for the prevention and treatment of skin disorders. In particular, the application describes topical compositions and methods of treatments comprising the combined use of one or more cannabinoids, or use of an ingredient that works on the endocannabinoid system, such as but not limited to, Palmitoylethanolamide (PEA), polyolprepolymers and stem cell extract.

Description

RELATED APPLICATION
This application claims the benefit of U.S. provisional application no. 62/692,178, filed Jun. 29, 2018 which is hereby incorporated by reference.
FIELD OF THE INVENTION
The present invention relates to compositions and methods for the prevention and treatment of skin disorders.
BACKGROUND OF THE INVENTION
The skin is the largest organ of the body, with a surface area of 18 square feet. In the epidermis, the keratinocytes produce keratin, a protein that gives skin its strength and flexibility and waterproofs the skin surface. Collagen and elastic fibers in the dermis give strength to the skin. The skin is continuously exposed to changes in the external environment, including oxidative insults, heat, cold, UV radiation, injury, and mechanical stresses. The stratum corneum, composed of terminally differentiated keratinocytes, constitutes the natural barrier that prevents loss of water and penetration of infectious agents, such as bacteria and viruses, and foreign particles. Keratin intermediate filaments provide the cells with mechanical resilience and protects them against physical stress. Disruption of the keratin scaffold leads to tissue and cell fragility in the skin and its appendages (hair, nail, glands), oral mucosa, and cornea, and exposes the skin to pathological conditions and diseases.
Dermatitis, also known as eczema, is an inflammation of the skin that is characterized by the presence of itchy, erythematous, vesicular, weeping, and crusting patches. Inflammatory agents include bacteria, fungi, viruses, and autoimmune, allergic, hormonal and malignant inflammatory agents. The most common skin diseases or disorders include eczema, psoriasis, dermatitis, itching dermatosis, rosacea, perioral dermatitis, acne, non-melanoma skin cancer and melanoma. Although symptoms vary, recurrent dermatitis conditions include pruritus, dryness and skin rashes, which may be accompanied by redness, skin swelling, itching and dryness, crusting, flaking, blistering, cracking, oozing, or bleeding. Common forms of dermatitis include atopic dermatitis and xerotic eczema.
Sunlight is a major cause of skin aging. Symptoms of photoaging are wrinkles, pigmentation, decreased skin elasticity, irregular texture and dryness. While treatment with moisturizers and steroid creams may temporarily control skin disorder and aging symptoms by reducing inflammation and smoothing wrinkles, the relief is only temporary. There is no known cure for dermatitis.
Accordingly, there is a need in the art for improved treatment options for improving skin condition, delaying and reducing the effects of skin aging and treating or preventing skin disorders.
SUMMARY OF THE INVENTION
It is, therefore, an object of the invention to provide solutions to the aforementioned problems, among other objects.
The present invention relates to compositions and methods for the prevention and treatment of skin disorders. In particular, provided herein are topical compositions and methods of treatment, comprising the combined use of one or more cannabinoids, or use of an ingredient that works on the endocannabinoid system, such as but not limited to, Palmitoylethanolamide (PEA), polyolprepolymers and stem cell extract.
In other embodiments, the present invention relates to the use of polyolprepolymers, stem cell medium extract and cannabinoids or compounds that act on endocannabinoid receptors for skin care.
One embodiment of the invention is a topical composition for treating skin that comprises a therapeutically effective amount of at least one cannabinoid or molecule that acts on endocannabinoid receptors (e.g., Palmitoylethanolamide (PEA)), and a therapeutically effective amount of a polyolprepolymer, stem cell extract and BV-OSC (tetrahexyldecy ascorbate). In other embodiments, at least one cannabinoid and either one up to all three of polyolprepolymer, stem cell extract and BV-OSC (tetrahexyldecy ascorbate), may be the only active ingredients of the composition. In one aspect of the linvention, the cannabinoids are present in the topical composition in a concentration between 0.1 and 30% by weight of the composition. Preferably, the cannabinoids are one or more of a natural phytocannabinoid, an organic cannabinoid, an endocannabinoid, a cannabinoid analog, a cannabinoid derivative, a synthetic cannabinoid and a cannabinoid receptor agonist. The polyolprepolymers include all compositions for facilitation permeation enhancement of the product into the skin outlined in U.S. Pat. No. 5,045,317, which is incorporated herein by reference in its entirety for all purposes. The stem cell medium extract are any multi-potent cell derived from human or plant stem cells used as a source of regenerative medicine. In one aspect of the invention, another active ingredient is Benzoyl Peroxide and all possible formulations of it.
In one aspect of the invention, the cannabinoid is hemp oil.
In a different aspect of the invention, the cannabinoid is one or more of cannabigerolic acid (CBGA), cannabigerolic acid monomethylether (CBGAM), cannabigerol (CBG), cannabigerol monomethylether (CBGM), cannabigerovarinic acid (CBGVA), cannabigerovarin (CBGV), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromevarinic acid (CBCVA), cannabichromevarin (CBCV), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabidiol monomethylether (CBDM), cannabidiol-C4 (CBD-C4), cannabidivarinic acid (CBDVA), cannabidivarin (CBDV), cannabidiorcol (CBD-C1), delta-9-tetrahydrocannabinolic acid A (THCA-A), delta-9-tetrahydrocannabinolic acid B (THCA-B), delta-9-tetrahydrocannabinol (THC), delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), delta-9-tetrahydrocannabinol-C4 (THC-C4), delta-9-tetrahydrocannabivarinic acid (THCVA), delta-9-tetrahydrocannabivarin (THCV), delta-9-tetrahydrocannabiorcolic acid (THCA-C1), delta-9-tetrahydrocannabiorcol (THC-C1), delta-7-cis-iso-tetrahydrocannabivarin, delta-8-tetrahydrocannabinolic acid (.DELTA8-THCA), delta-8-tetrahydrocannabinol (.DELTA8-THC), cannabicyclolic acid (CBLA), cannabicyclol (CBL), cannabicyclovarin (CBLV), cannnabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabielsoin (CBE), cannabinolic acid (CBNA), cannabinol (CBN), cannabinol methylether (CBNM), cannabinol-C4 (CBN-C4), cannabivarin (CBV), cannabinol-C2 (CBN-C2), cannabiorcol (CBN-C1), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabitriol (CBT), 10-ethoxy-9-hydroxy-delta-6a-tetrahydrocannabinol, 8,9-dihydroxy-delta-6a-tetrahydrocannabinol, cannabitriolvarin (CBTV), ethoxy-cannabitriolvarin (CBTVE), dehydrocannabifuran (DCBF), cannabifuran (CBF), cannabichromanon (CBCN), cannabicitran (CBT), 10-oxo-delta-6a-tetrahydrocannabinol (OTHC), delta-9-cis-tetrahydrocannabinol (cis-THC), 3,4,5,6-tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-metha-no-2H-1-benzoxocin-5-methanol (OH-iso-HHCV), cannabiripsol (CBR) and trihydroxy-delta-9-tetrahydrocannabinol (triOH-THC).
In yet another aspect of the invention, the cannabinoid is a cannabinoid receptor agonist. Preferably, the cannabinoid receptor agonist comprises one or more of a naphthoylindole, a naphthylmethylindole, a naphthoylpyrrole, a naphthylmethylindene, a phenylacetylindole, a cyclohexylphenol and a Palmitoylethanolamide (PEA).
In one embodiment of the invention, the benzoyl peroxide is present in the topical composition in a concentration between 0.1 and 10% by weight of the composition.
In one embodiment, the topical composition may further comprise a stabilizer. Preferably, the stabilizer is selected from the group consisting of guar gum, xanthan gum cellulose hyaluronic acid, polyvinyl pyrrolidone (PVP), alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitisin, corn starch and flour, and is present in an amount from about 0.25% to about 30% (w/v).
In a preferred aspect of the invention, the topical composition is in the form of an ointment, a cream, an emulsion, a lotion, a paste, an unguent, a gel or a sunscreen. In yet another preferred aspect, the carrier in the topical composition comprises hemp oil.
In one embodiment, the topical composition further comprises one or more of a thickening agent, an antibiotic, an antiseptic agent, an antifungal, an antibacterial agent, an analgesic or an antiviral agent. In one aspect of the invention, the topical composition may further comprises a UV absorbing agent in an amount between 0.1 and 5% by weight of the composition.
In a different embodiment, the invention provides a method of treating skin, treating a skin disorder, or improving a condition of the skin in a subject in need thereof comprising topically administering to the subject the topical composition of the invention as described above. In one aspect of the invention, the skin disorder is one or more of atopic dermatitis or eczema, psoriasis, dermatitis, itching dermatosis, seborrheic dermatitis, rosacea, perioral dermatitis, acne, non-melanoma cancer or melanoma. In another aspect of the invention, the subject presents a symptom which is one or more of pruritus, dryness, skin rash, redness, swelling of the skin, itching, crusting, flaking, blistering, cracking, oozing, or bleeding. In yet another aspect, the dermatitis is atopic dermatitis, contact dermatitis, xerotic eczema, or seborrheic dermatitis. Preferably, the composition of the invention is topically administered to the subject in an amount between about 100 nmol to about 1 .mu.mol/cm2. In one aspect of the invention, the subject is a mammal. In a preferred aspect of the invention, the mammal is a human.
In yet another embodiment, the invention provides a method for treating or preventing pruritus, dryness of the skin, skin rash, redness, swelling of the skin, itching, crusting, flaking, blistering, cracking, oozing, bleeding or blistering of the skin in a subject in need thereof, that comprises topically administering to the subject the composition of the invention. In one aspect of the invention, the subject has one or more of eczema, psoriasis, dermatitis, itching dermatosis, rosacea, perioral dermatitis, acne, non-melanoma cancer or melanoma. In one embodiment, the dermatitis is atopic dermatitis, contact dermatitis, xerotic eczema, or seborrheic dermatitis. Preferably, the composition of the invention is topically administered to the subject in an amount between about 100 nmol to about 1 .mu.mol/cm2. In one aspect of the invention, the subject is a mammal. In a preferred aspect of the invention, the mammal is a human.
The foregoing general description and following brief description of the drawings and the detailed description are exemplary and explanatory and are intended to provide further explanation of the invention as claimed. Other objects, advantages, and novel features will be readily apparent to those skilled in the art from the following detailed description of the invention.
FIG. 1 of US 2018/0021241A1, which is incorporated herein by reference in its entirety for all purposes, illustrates the chemical structure of some cannabinoids for use according to the invention.
DETAILED DESCRIPTION OF THE INVENTION
Cannabinoids are terpenophenolic compounds found in Cannabis sativa, an annual plant belonging to the Cannabaceae family. The plant contains more than 400 chemicals and approximately 80 cannabinoids. The latter accumulate mainly in the glandular trichomes. Natural phytocannabinoids occur in the free acid forms within plant tissue. For instance, the psychoactive cannabinoids tetrahydrocannbinol (THC), cannabidiol (CBD), cannabichromene (CBC) and cannabigerol (CBG) exist in their corresponding carboxylic acid forms THCA, CBDA, CBCA and CBGA within plant tissue and are converted to their active forms via non-enzymatic decarboxylation that occurs upon the drying of the plant tissue, or during storage or smoking.
The most active of the naturally occurring cannabinoids is tetrahydrocannabinol (THC), which is used for treating a wide range of medical conditions, including glaucoma, AIDS wasting, neuropathic pain, treatment of spasticity associated with multiple sclerosis, fibromyalgia and chemotherapy-induced nausea. Additionally, THC has been reported to be effective for the treatment of allergies, inflammation, infection, epilepsy, depression, migraine, bipolar disorders, anxiety disorder, drug dependency and drug withdrawal syndromes.
Cannabidiol (CBD), an isomer of THC, is a potent antioxidant and anti-inflammatory compound known to provide protection against acute and chronic neurodegeneration, and relief from chronic pain, inflammation, migraines, arthritis, spasms, epilepsy, and the like.
Cannabigerol (CBG), which is found in high concentrations in hemp, acts as a high affinity .alpha2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist and low affinity CB1 receptor antagonist, and thus may have anti-depressant activity. Cannabichromene (CBC) possesses anti-inflammatory, anti-fungal and anti-viral properties. Tetrahydrocannabivarin (THCV) is known as an appetite suppressant.
The use of cannabinoids in topical compositions is limited by the fact that cannabinoids, because of their hydrophobic nature, must be dissolved in organic solvents that may irritate the skin.
Polyolprepolymers are polyalkylene glycol-based polyurethane polymers that readily deposit on and within the stratum corneum forming a reservoir rather than migrating further into the skin. In one aspect of the invention, the polyolprepolymers are present in the topical composition in a concentration between 0.1 and 30% by weight of the total composition. In other embodiments of the invention, the polyolprepolymers are present in the topical composition in a concentration between 0.1 and 25%, between 0.1 and 20%, between 0.1 and 15%, between 0.1 and 10%, or between 0.1 and 5% by weight of the total composition. This increases the efficacy of skin care formulations. This includes but is not limited to polyolprepolymer-2, polyolprepolymer-14 and polyolprepolymer-15, outlined in U.S. Pat. No. 5,045,317.
Alpha and beta hydroxy acids are chemical exfoliants. Alpha hydroxy acids are carboxylic acids characterized by the presence of one hydroxyl group attached to the .alpha.-position of the carboxyl group, known for their beneficial exfoliating properties and for inducing skin proliferation and new cell growth. Exemplary alpha-hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, citric acid and tartaric acid. Alpha-hydroxy acids are different from beta-hydroxy acids, such as .beta.-hydroxybutanoic acid, which are carboxylic acids characterized by having one hydroxyl group attached to the .beta.-position of the carboxyl group.
In accordance with the present invention, it is contemplated herein that compositions containing polyolprepolymers, BV-OSC and stem cell extract in combination with one or more cannabinoids provide a number of advantages not found when either active agent is used by itself, including reduced skin irritation and fast healing of any skin condition that is enhanced by inflammation including, but not limited to, acne, aging spots, scar formation, eczema and wrinkles. Without being bound to any theory, it is believed that the cannabinoids of the inventive compositions modulate the cannabinoid receptors CB1R and CB2R located in the skin and involved in the attenuation of pain and contact allergic reaction, and thus stimulate the proliferation, growth and differentiation of keratinocytes in the skin as well as their immune competence and/or tolerance. Furthermore, it is believed that the combination of the cannabinoids with polyolprepolymers results in an unexpected synergic anti-inflammatory effect due to the anti-inflammatory properties of the cannabinoids, and contributes to the total wellness of the skin. Accordingly, the compositions containing a combination of one or more polyolprepolymers and one or more cannabinoids according to the invention provide greater skin improvement effects than the same compositions comprising either alone.
One embodiment of the invention is a topical composition for treating skin that comprises a therapeutically effective amount of at least one cannabinoid or molecule that acts on endocannabinoid receptors (e.g., Palmitoylethanolamide (PEA)), and a therapeutically effective amount of a polyolprepolymer, stem cell extract and BV-OSC (tetrahexyldecy ascorbate). In one embodiment of the invention, the stem cell extract is present in the topical composition in a concentration between 0.1 and 30% by weight of the composition. In other embodiments of the invention, the stem cell extract is present in the topical composition in a concentration between 0.1 and 25%, between 0.1 and 20%, between 0.1 and 15%, between 0.1 and 10%, or between 0.1 and 5%, by weight of the total composition. Likewise, in one aspect of the invention, the BV-OSC is present in the topical composition in a concentration between 0.1 and 30% by weight of the composition. In other embodiments of the invention, the BV-OSC is present in the topical composition in a concentration between 0.1 and 25%, between 0.1 and 20%, between 0.1 and 15%, between 0.1 and 10%, or between 0.1 and 5%, by weight of the total composition.
As used herein, the terms “cannabinoid” and “cannabinoids” include, but are not limited to, natural phytocannabinoids, organic cannabinoids, endocannabinoids, cannabinoid analogs, cannabinoid derivatives, synthetic cannabinoids and cannabinoid receptor agonists.
Examples of organic cannabinoids include, but are not limited to, hemp oil.
Examples of cannabinoids, cannabinoid analogs and cannabinoid derivatives include, but are not limited to, cannabigerolic acid (CBGA), cannabigerolic acid monomethylether (CBGAM), cannabigerol (CBG), cannabigerol monomethylether (CBGM), cannabigerovarinic acid (CBGVA), cannabigerovarin (CBGV), cannabichromenic acid (CBCA), cannabichromene (CBC), cannabichromevarinic acid (CBCVA), cannabichromevarin (CBCV), cannabidiolic acid (CBDA), cannabidiol (CBD), cannabidiol monomethylether (CBDM), cannabidiol-C4 (CBD-C4), cannabidivarinic acid (CBDVA), cannabidivarin (CBDV), cannabidiorcol (CBD-C1), delta-9-tetrahydrocannabinolic acid A (THCA-A), delta-9-tetrahydrocannabinolic acid B (THCA-B), delta-9-tetrahydrocannabinol (THC), delta-9-tetrahydrocannabinolic acid-C4 (THCA-C4), delta-9-tetrahydrocannabinol-C4 (THC-C4), delta-9-tetrahydrocannabivarinic acid (THCVA), delta-9-tetrahydrocannabivarin (THCV), delta-9-tetrahydrocannabiorcolic acid (THCA-C1), delta-9-tetrahydrocannabiorcol (THC-C1), delta-7-cis-iso-tetrahydrocannabivarin, delta-8-tetrahydrocannabinolic acid (.DELTA8-THCA), delta-8-tetrahydrocannabinol (.DELTA8-THC), cannabicyclolic acid (CBLA), cannabicyclol (CBL), cannabicyclovarin (CBLV), cannnabielsoic acid A (CBEA-A), cannabielsoic acid B (CBEA-B), cannabielsoin (CBE), cannabinolic acid (CBNA), cannabinol (CBN), cannabinol methylether (CBNM), cannabinol-C4 (CBN-C4), cannabivarin (CBV), cannabinol-C2 (CBN-C2), cannabiorcol (CBN-C1), cannabinodiol (CBND), cannabinodivarin (CBVD), cannabitriol (CBT), 10-ethoxy-9-hydroxy-delta-6a-tetrahydrocannabinol, 8,9-dihydroxy-delta-6a-tetrahydrocannabinol, cannabitriolvarin (CBTV), ethoxy-cannabitriolvarin (CB TVE), dehydrocannabifuran (DCBF), cannabifuran (CBF), cannabichromanon (CBCN), cannabicitran (CBT), 10-oxo-delta-6a-tetrahydrocannabinol (OTHC), delta-9-cis-tetrahydrocannabinol (cis-THC), 3,4,5,6-tetrahydro-7-hydroxy-alpha-alpha-2-trimethyl-9-n-propyl-2,6-metha-no-2H-1-benzoxocin-5-methanol (OH-iso-HHCV), cannabiripsol (CBR) and trihydroxy-delta-9-tetrahydrocannabinol (triOH-THC).
Cannabinoid receptor agonists as used herein may include natural and synthetic compounds that are structurally related to natural cannabinoids, and natural and synthetic compounds that are not structurally related to natural cannabinoids, all of which interact with at least one of the cannabinoid receptors. Cannabinoid receptor agonists that can be used according to the invention exert the same function as natural cannabinoids and share one or more common features with natural cannabinoids. For example, cannabinoid receptor agonists that are not structurally related to natural cannabinoids are lipid soluble and non-polar, consist of 22 to 26 carbon atoms and have a side-chain comprising more than four and up to nine saturated carbon atoms. Non-limiting examples of cannabinoid receptor agonists that are not structurally related to natural cannabinoids include naphthoylindoles, naphthylmethylindoles, naphthoylpyrroles, naphthylmethylindenes, phenylacetylindoles, such as benzoylindoles, cyclohexylphenols, and Palmitoylethanolamide (PEA).
Exemplary cannabinoid receptor agonists are well known in the art and include, but are not limited to, compounds of the molecular formula C21H30O2; the molecular formula C25H38O3; the molecular formula C21H34O2; the molecular formula C24H23NO; the molecular formula C22H25NO2; and the like.
Accordingly, the present invention provides a topical composition and methods for the treatment of a skin disorder or rejuvenation of the skin that comprise administering a topical composition, wherein the topical composition comprises a therapeutically effective amount of at least one cannabinoid and a therapeutically effective amount of at least one polyolprepolymers in a pharmaceutically acceptable carrier. Preferably, the carrier is an oil, cream or ointment.
In one aspect of the invention, the cannabinoids are present in the topical composition in a concentration between 0.1 and 30% by weight of the composition. In other embodiments of the invention, the cannabinoids are present in the topical composition in a concentration between 0.1 and 25%, between 0.1 and 20%, between 0.1 and 15%, between 0.1 and 10%, or between 0.1 and 5%, by weight of the total composition. Preferably, the cannabinoids are one or more of tetrahydrocannbinol (THC), cannabidiol (CBD), cannabigerol (CBG), cannabichromene (CBC), tetrahydrocannabivarin (THCV), analogs thereof, derivatives thereof, organic and synthetic cannabinoids and cannabinoid receptor agonists as described above. In one aspect of the invention, the cannabinoids in the topical composition comprise one or more of a natural phytocannabinoid, an organic cannabinoid, an endocannabinoid, a cannabinoid analog, a cannabinoid derivative, a synthetic cannabinoid and a cannabinoid receptor agonist. The cannabinoid receptor agonist may comprise one or more of a naphthoylindole, a naphthylmethylindole, a naphthoylpyrrole, a naphthylmethylindene, a phenylacetylindole, a cyclohexylphenol, and a Palmitoylethanolamide (PEA).
As used herein, the term “hydroxy acid” includes, but is not limited to, alpha-hydroxy acid and beta-hydroxy acid. The hydroxy acids are present in the topical composition in a concentration between 0.1 and 10% by weight of the composition. Alpha hydroxy acids that may be used according to the invention comprise, but are not limited to, organic carboxylic acids in which one hydroxyl group is attached to the alpha carbon of the acids. The generic structure of alpha hydroxy acids may be represented by the formula (Ra) (Rb) C (OH) COOH, wherein Ra and Rb are each H, F, Cl, Br, alkyl, aralkyl or aryl group of saturated or unsaturated, isomeric or non-isomeric, straight or branched chain or cyclic form, having 1 to 25 carbon atoms. Ra and Rb may also carry an OH, CHO, COOH or alkoxy group having 1 to 9 carbon atoms. The hydroxy acids may be present in the topical composition as a free acid or in lactone form, or in a salt form with an organic base or an inorganic alkali. The hydroxy adds may also exist as stereoisomers as D, L, and DL forms when Ra and Rb are not identical.
Typical alkyl, aralkyl and aryl groups for Ra and Rb include, but are not limited to, methyl, ethyl, propyl, isopropyl, butyl, pentyl, octyl, lauryl, stearyl, benzyl and phenyl. Alpha hydroxy acids include (1) alkyl alpha hydroxyacids; (2) aralkyl and aryl alpha hydroxyacids; (3) polyhydroxy alpha hydroxyacids; and (4) polycarboxylic alpha hydroxyacids.
Alkyl alpha hydroxy acids include, but are not limited to, 2-hydroxyethanoic acid (glycolic acid, hydroxyacetic acid) (H) (H) c (OH) COOH; 2-hydroxypropanoic acid (lactic acid) (CH3) (s) C (OH) COOH; 2-methyl 2-hydroxypropanoic acid (methyllactic acid) (CH3) (CH3) C (OH) COOH; 2-hydroxybutanoic acid (C2 H5) (H) C (OH) COOH, 2-hydroxypentanoic acid (C3 H7) (H) C (OH) COOH; 2-hydroxyhexanoic acid (C4 H9) (H) C (OH) COOH; 2-hydroxyheptanoic acid (C5 H11 (H) C (OH) COOH; 2-hydroxyoctanoic acid (C6 H13) (H) C (OH) COOH; 2-hydroxynonanoic acid (C7 H15) (H) C (OH) COOH; 2-hydroxydecanoic acid C8 H17) (H) C (OH) COOH; 2-hydroxyundecanoic acid (C10 H19) (H) C (OH) COOH; 2-hydroxydodecanoic acid (alpha hydroxylauric acid) (C10 H21) (H) C (OH) COOH, 2-hydroxytetradecanoic acid (alpha hydroxymyristic acid) (C12 H25) (H) C (OH) COOH; 2-hydroxyhexadecanoic acid (alpha hydroxypalmitic acid) C14 H29) (H) C (OH) COOH; 2-hydroxyoctadecanoic acid (alpha hydroxystearic acid) (C16 H14) (H) C (OH) COOH; 2-hydroxyeicosanoic acid (alpha hydroxyarachidonic acid) (C18 H37) (H) (OH) COOH.
Aralkyl and aryl alpha hydroxy acids include, but are not limited to, 2-phenyl 2-hydroxyethanoic acid (mandelic acid) (C6 H5) (H) C (OH) COOH; 2,2-diphenyl 2-hydroxyethanoic acid (benzylic acid) (C6 H5) (C6 H5) C (OH) COOH; 3-pphenyl 2-hydroxypropanoic acid (phenyllactic acid) (C6 H5 CH2) (H) C (OH) COOH; 2-pphenyl 2-methyl 2-hydroxyethanoic acid (atrolactic acid) (C6 H5) (CH3) C (OH) COOH; 2-(4′-hydroxyphenyl)2-hydroxyethanoic acid (4-hydroxymandelic acid) (HO═C6 H4) (H) C (OH) COOH; 2-(4′-chlorophenyl) 2-hydroxyethanoic acid (4-chloromandelic acid) (Cl═C6 H4) (H) C (OH) COOH; 2-(3′-hydroxy-4′-methoxyphenyl) 2-hydroxyethanoic acid (3-hydroxy-4-methoxymandelic acid) (HO═, CH3 O═C6 H3) (H) C (OH) COOH; 2-(4′-hydroxy-3′-methoxyphenyl) 2-hydroxyethanoic acid (4-hydroxy-3-methoxymandelic acid) (HO═, CH3 O═C6 H3) (H) C (OH) COOH; 3-(2′-hydroxyphenyl)2-hydroxypropanoic acid [3-(2′-hydroxyphenyl) lactic acid]HO═C6 H4═CH2 (H) C (OH) COOH; 3-(4′-hydroxyphenyl) 2-hydroxypropanoic acid [3-(4′-hydroxyphenyl) lactic acid]HO═C6═CH2 (H) C (OH) COOH; and 2-(3′,4′-dihydroxyphenyl) 2-hydroxyethanoic acid (3,4-dihydroxymandelic acid) HO═, HO═C6 H3 (H) C (OH) COOH.
Polyhydroxy alpha hydroxy acids include, but are not limited to, 2,3-dihydroxypropanoic acid (glyceiic acid) (HOCH2) (H) C (OH) COOH; 2,3,4-trihydroxybutanoic acid (isomers; erythronic acid, threonic acid) HOCH2 (HO)CH2 (H) C (OH) COOH; 2,3,4,5-tetrahydroxypentanoic acid (isomers; ribonic acid, arabinoic acid, xylonic acid, lyxonic acid) HOCH2 (HO) CH2(HO) CH2 (H) C (OH) COOH; 2,3,4,5,6-pentahydroxyhexanoic acid (Isomers; allonic acid, altronic acid, gluconic acid, mannoic acid, gulonic acid, idonic acid, galactonic acid, talonic acid) HOCH2 (HO)CH2 (HO)CH2 (HO)CH2 (H) C (OH) COOH; and 2,3,4,5,6,7-hexahydroxyheptanoic acid (isomers; glucoheptonic acid, galactoheptonic acid etc.) HOCH2 (HO) CH2 (HO) CH2 (HO) CH2 (HO) CH2 (H) C (OH) COOH.
Polycarboxylic alpha hydroxy acids include, but are not limited to, 2-hydroxypropane-1,3-dioic acid (tartronic acid) HOOC (H) C (OH) COOH; 2hydroxybutane-1,4-dioic acid (malic acid) HOOC CH2 (H) C (OH) COOH; 2,3-dihydroxybutane-1,4-dioic acid (tartaric acid) HOOC (HO)CH (Hi) C (OH) COOH; 2-hydroxy-2-carboxypentane-1,5-dioic acid (citric acid) HOOC CH2 C (OH) (COOH) CH2 COOH; 2,3,4,5-tetrahydroxyhexane-1,6-dioic acid (isomers; saccharic acid, mucic acid etc.) HOOC (CHOH)4 COOH.
Lactone forms include, but are not limited to, gluconolactone, galactonolactone, glucuronolactone, galacturonolactone, gulonolactone, ribonolactone, saccharic acid lactone, pantoyllactone, glucoheptonolactone, mannonolactone, and galactoheptonolactone.
In a preferred aspect of the invention, the alpha hydroxy acid is lactic acid, citric acid, glycolic acid, mandelic acid, benzylic acid, malic acid, tartaric acid, gluconolactone, galactonolactone, glucuronolactone, galacturonolactone, gulonolactone, ribonolactone, saccharic acid lactone, pantoyllactone, glucoheptonolactone, mannonolactone, or galactoheptonolactone. In an additional preferred aspect of the invention, the beta-hydroxy acid is salicylic acid. In additional preferred aspects of the invention the polyolprepolymers is PP-2, PP-14, or PP-15. In additional preferred aspects of the invention, benzoyl peroxide is present from 0.1% up to 10% by weight of the total composition.
In one embodiment, the topical composition may further comprise a stabilizer. Preferably, the stabilizer is selected from the group consisting of guar gum, xanthan gum cellulose hyaluronic acid, polyvinyl pyrrolidone (PVP), alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitisin, corn starch and flour, and is present in an amount from about 0.25% to about 30% (w/v).
In a preferred aspect of the invention, the topical composition is in the form of an ointment, a cream, an emulsion, a lotion, a paste, an unguent, a gel or a sunscreen. In yet another preferred aspect, the carrier in the topical composition comprises hemp oil.
Creams according to the inventions include water-in-oil or oil-in-water emulsions and may further comprise a cleansing agent, an emollient and an aromatic chemical compound.
Ointments and unguents according to the invention optionally contain oil and water in a ratio from 2:1 to 7:1, and may further comprise a wax, alcohols and petroleum-based mollifying agents.
Gels according to the invention optionally contain a vegetable oil up to 5% by weight of the total composition, water and a thickening agent. Preferably, the thickening agent is a natural polysaccharide, such as xanthan gum, carrageen, an alginate or cellulose gum.
Pastes according to the invention may optionally contain aloe gel and beeswax.
Lotions according to the invention include oil-in-water or water-in-oil emulsions and may comprise cetyl alcohol, an emulsifier, a fragrance, glycerol, petroleum jelly, a dye, one or more preservatives and a stabilizing agent.
A sunscreen composition according to the invention may further comprise a UV absorbing or barrier agent in an amount between 0.1 and 10% by weight of the composition. Exemplary UV-absorbing compounds include, but are not limited to, benzone compounds, glyceryl PABA, roxadimate, octocrylene, octyl methoxycinnamate, ethoxyethyl p-methoxycinnamate, homomenthyl salicylate, ethylhexyl salicylate, trolamine salicylate, ecamsule, ensulizole, bemotrizinol and bisoctrizole. Exemplary UV-barrier compounds include but are not limited to, zinc oxide and titanium dioxide.
In some embodiments, the topical compositions of the invention may further comprise one or more active agents, such as an antibiotic, an antiseptic agent, an antifungal, an antibacterial agent, an analgesic or an antiviral agent. In additional embodiments, the topical compositions of the invention may further comprise anesthetics, anti-cancer agents, antiacne agents, humectants, such as cationic, ionic and non-ionic surfactant, moisturizers, antipruritic agents, antiperspirants, antipsoriatic agents, antiseborrheic agents, antiaging and anti-wrinkle agents, skin lightening agents, depigmenting agents and vitamins.
Exemplary antibiotics include, but are not limited to, ampicillin, bacampicillin, carbenicillin indanyl, mezlocillin, piperacillin, ticarcillin, amoxicillin-clavulanic acid, ampicillin-sulbactam, benzylpenicillin, cloxacillin, dicloxacillin, methicillin, oxacillin, penicillin G, penicillin V, piperacillin tazobactam, ticarcillin clavulanic acid, nafcillin, procaine penicillin, cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin, cephradine, cefaclor, cefamandol, cefonicid, cefotetan, cefoxitin, cefprozil, ceftmetazole, cefuroxime, loracarbef cefdinir, ceftibuten, cefoperazone, cefixime, cefotaxime, cefpodoxime proxetil, ceftazidime, ceftizoxime, ceftriaxone, cefepime, azithromycin, clarithromycin, clindamycin, dirithromycin, erythromycin, lincomycin, troleandomycin, cinoxacin, ciprofloxacin, enoxacin, gatifloxacin, grepafloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, sparfloxacin, trovafloxacin, oxolinic acid, gemifloxacin, perfloxacin, imipenem-cilastatin, meropenem, and aztreonam. In one embodiment, the amount of the antibiotic in the composition is from 0.01 to 5% by weight of the total composition.
Antiseptic compounds include, but are not limited to, iodine, manuka honey, octenidine dihydrochloride, phenol, polyhexanide, sodium chloride, sodium hypochlorite, calcium hypochlorite, sodium bicarbonate, methyl paraben, benzoyl peroxide and sodium dehydroacetate. In one embodiment, the amount of the antiseptic compound in the topical formulation is from 0.01 to 5% by weight of the total composition.
Antifungal agents include, but are not limited to, amphotericin B, candicidin, filipin, hamycin, natamycin, nystatin, rimocidin, bifonazole, butoconazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, luliconazole, miconazole, omoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, albaconazole, fluconazole, isavuconazole, itraconazole, posaconazole, ravuconazole, terconazole, voriconazole, abafungin, amorolfin, butenafine, naftifine, terbinafine, anidulafungin, caspofungin, micafungin, benzoic acid, ciclopirox, flucytosine, griseofulvin, haloprogin, tolnaftate, undecylenic acid, crystal violet, and balsam of Peru. In one embodiment, the amount of the antifungal agent in the topical formulation is from 0.01 to 5% by weight of the total composition.
Analgesic agents include, but are not limited to, methyl salicylate, codeine, morphine, methadone, pethidine, buprenorphine, hydromorphine, levorphanol, oxycodone, fentanyl, and a non-steroidal anti-inflammatory drug. The amount of the analgesic agent in the topical formulation is from 0.01 to 5% by weight of the total composition.
Anti-viral agents include, but are not limited to, acyclovir, famciclovir, penciclovir, valacyclovir, trifluridine, docosanol, amantadine, rimantadine, oseltamivir, and zanamivir. The amount of the anti-viral agent in the topical formulation is from 0.01 to 5% by weight of the total composition.
In some embodiments, the topical composition of the invention may further comprise a stabilizer selected from the group consisting of guar gum, xanthan gum cellulose hyaluronic acid, polyvinyl pyrrolidone (PVP), alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitisin, corn starch and flour, in an amount from about 0.25% to about 2% (w/v).
In some embodiments, the composition for topical application to the skin comprises a therapeutically effective amount of at least one cannabinoid, a therapeutically effective amount of polyolprepolymers.
The cannabinoids according to the invention may be obtained as an extract from a cannabis plant for medical use, such as Cannabis sativa and Cannabis indica, by extracting the trichomes of the plants in a solvent and heating the mixture to evaporate the solvent. Examples of extraction technologies that may be used include, but are not limited to, CO2 extraction and microwave extraction. The cannabinoids according to the invention may also be obtained as an extract from a cannabis transgenic plant that overexpresses one or more particular cannabinoids or that does not express or under-expresses one or more particular cannabinoids. Synthetic cannabinoids may be prepared according to the technologies known to those skilled in the art. In the alternative, endogenous nucleic acid sequences may be extracted from a cannabis plant and used to produce cannabinoids by recombinant technology.
The topical compositions of the invention may be prepared by dissolving the dry extracts of cannabinoids in an oil, and by adding the cannabinoid solution to a composition containing the hydroxy acids. The hydroxy acid composition may be an alcohol solution in which the hydroxy acids are dissolved, or the hydroxy acids may be dissolved in an alcohol-free solution. In an alternative embodiment, the hydroxy acids are dissolved in a composition comprising hemp oil or one or more cannabinoid, analogs thereof, derivatives thereof, organic and synthetic cannabinoids and cannabinoid receptor agonists as described above, wherein the one or more cannabinoids, analogs thereof, derivatives thereof, organic and synthetic cannabinoids and cannabinoid receptor agonists are dissolved in an oil. Preferably, the oil is a vegetable oil. Even more preferably the vegetable oil is hemp oil.
In a different embodiment, the invention provides a method to treat a skin disorder or rejuvenate the skin in a subject in need thereof, that comprises topically administering to the subject the topical composition of the invention as described above. The skin disorder may be one or more of eczema, psoriasis, dermatitis, itching dermatosis, rosacea, perioral dermatitis, acne, non-melanoma cancer or melanoma. The subject may present the first signs of irritation, or presents a severe symptom which is one or more of pruritus, dryness, skin rash, redness, swelling of the skin, itching, crusting, flaking, blistering, cracking, oozing, and bleeding. The dermatitis may be atopic dermatitis, contact dermatitis, xerotic eczema, or seborrheic dermatitis. In a preferred embodiment, the composition of the invention is topically administered to the subject in an amount between about 100 nmol to about 1 .mu.mol/cm2. In one aspect of the invention, the subject is a mammal. In a preferred aspect of the invention, the mammal is a human.
In yet another embodiment, the invention provides a method for treating or preventing pruritus, dryness of the skin, skin rash, redness, swelling of the skin, itching, crusting, flaking, blistering, cracking, oozing, bleeding or blistering of the skin in a subject in need thereof, that comprises topically administering to the subject the composition of the invention. The subject may be disease-free or may be suspected of having or have one or more skin conditions, such as eczema, psoriasis, dermatitis, itching dermatosis, rosacea, perioral dermatitis, acne, non-melanoma cancer or melanoma. The dermatitis may be atopic dermatitis, contact dermatitis, xerotic eczema, or seborrheic dermatitis. In a preferred embodiment, the composition of the invention is topically administered to the subject in an amount between about 100 nmol to about 1 .mu.mol/cm2. In one aspect of the invention, the subject is a mammal. In a preferred aspect of the invention, the mammal is a human.
The present invention thus generally described, will be understood more readily by reference to the following examples, which are provided by way of illustration only, and are not intended to be limiting the present invention.
EXAMPLES Example 1 Treatment of Dermatitis
30 subjects with severe dermatitis are divided into two groups, 5 subjects per group. The subjects are instructed to topically apply a cream two times daily for two weeks. Group one is treated for two weeks with a cream containing hydroxyl acids, polyolprepolymer, stem cell extract and vehicle. Group two is treated for two weeks with a cream containing the hydroxyl acids, polyolprepolymer, stem cell extract, vehicle and cannabinoids. The effects of the different treatments are evaluated after two weeks.

Claims (15)

The invention claimed is:
1. A topical emulsion consisting essentially of an isolated cannabinoid selected from the group consisting of cannabigerolic acid, cannabigerolic acid monomethylether, cannabigerol, cannabigerol monomethylether, cannabigerovarinic acid, cannabigerovarin, cannabichromenic acid, cannabichromene, cannabichromevarinic acid, cannabichromevarin, cannabidiolic acid, cannabidiol, cannabidiol monomethylether, cannabidiol-C4, cannabidivarinic acid, cannabidivarin, cannabidiorcol and mixtures thereof; a stem cell extract; and a polyolprepolymer.
2. The topical emulsion of claim 1, wherein the cannabinoid is present in a concentration between 0.1 and 30% by weight of the topical emulsion; and wherein the polyolprepolymer is present in a concentration between 0.1 and 10% by weight of the topical emulsion.
3. The topical emulsion of claim 1, wherein the polyolprepolymer is polyolprepolymer-2, -14, or -15, or a combination thereof.
4. The topical emulsion of claim 1, further consisting essentially of tetrahexylecyl ascorbate.
5. The topical emulsion of claim 1, further consisting essentially of a component selected from the group consisting of an alpha hydroxy acid, a lactic acid, citric acid, glycolic acid, mandelic acid, benzylic acid, malic acid, tartaric acid, gluconolactone, galactonolactone, glucuronolactone, galacturonolactone, gulonolactone, ribonolactone, saccharic acid lactone, pantoyllactone, glucoheptonolactone, mannonolactone, galactoheptonolactone and mixtures thereof.
6. The topical emulsion of claim 1, further consisting essentially of a benzoyl peroxide.
7. The topical emulsion of claim 1, further consisting essentially of a hydroxy acid.
8. The topical emulsion of claim 1, further consisting essentially of a stabilizer selected from the group consisting of guar gum, xanthan gum, cellulose, hyaluronic acid, polyvinyl pyrrolidone, alginate, chondritin sulfate, poly gamma glutamic acid, gelatin, chitosin, corn starch, flour and mixtures thereof, in an amount from about 0.25% to about 30% (w/v).
9. The topical emulsion of claim 1, further consisting essentially of hemp oil.
10. The topical emulsion of claim 1, further consisting essentially of one or more of a thickening agent, an antibiotic, an antiseptic agent, an antifungal, an analgesic, an antiviral agent or a UV absorbing agent in an amount between 0.1 and 5% by weight of the composition;
wherein the thickening agent is selected from the group consisting of xanthan gum, carrageen, an alginate and cellulose gum;
wherein the antibiotic is selected from the group consisting of ampicillin, bacampicillin, carbenicillin indanyl, mezlocillin, piperacillin, ticarcillin, amoxicillin-clavulanic acid, ampicillin-sulbactam, benzylpenicillin, cloxacillin, dicloxacillin, methicillin, oxacillin, penicillin G, penicillin V, piperacillin tazobactam, ticarcillin clavulanic acid, nafcillin, procaine penicillin, cefadroxil, cefazolin, cephalexin, cephalothin, cephapirin, cephradine, cefaclor, cefamandol, cefonicid, cefotetan, cefoxitin, cefprozil, ceftmetazole, cefuroxime, loracarbef cefdinir, ceftibuten, cefoperazone, cefixime, cefotaxime, cefpodoxime proxetil, ceftazidime, ceftizoxime, ceftriaxone, cefepime, azithromycin, clarithromycin, clindamycin, dirithromycin, erythromycin, lincomycin, troleandomycin, cinoxacin, ciprofloxacin, enoxacin, gatifloxacin, grepafloxacin, levofloxacin, lomefloxacin, moxifloxacin, nalidixic acid, norfloxacin, ofloxacin, sparfloxacin, trovafloxacin, oxolinic acid, gemifloxacin, perfloxacin, imipenem-cilastatin, meropenem, aztreonam, and mixtures thereof;
wherein the antiseptic agent is selected from the group consisting of iodine, manuka honey, octenidine dihydrochloride, phenol, polyhexanide, sodium chloride, sodium hypochlorite, calcium hypochlorite, sodium bicarbonate, methyl paraben, benzoyl peroxide, sodium dehydroacetate, and mixtures thereof;
wherein the antifungal is selected from the group consisting of amphotericin B, candicidin, filipin, hamycin, natamycin, nystatin, rimocidin, bifonazole, butoconazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, luliconazole, miconazole, omoconazole, oxiconazole, sertaconazole, sulconazole, tioconazole, albaconazole, fluconazole, isavuconazole, itraconazole, posaconazole, ravuconazole, terconazole, voriconazole, abafungin, amorolfin, butenafine, naftifine, terbinafine, anidulafungin, caspofungin, micafungin, benzoic acid, ciclopirox, flucytosine, griseofulvin, haloprogin, tolnaftate, undecylenic acid, crystal violet, balsam, and mixtures thereof;
wherein the analgesic is selected from the group consisting of methyl salicylate, codeine, morphine, methadone, pethidine, buprenorphine, hydromorphine, levorphanol, oxycodone, fentanyl, and mixtures thereof;
wherein the antiviral agent is selected from the group consisting of acyclovir, famciclovir, penciclovir, valacyclovir, trifluridine, docosanol, amantadine, rimantadine, oseltamivir, zanamivir, and mixtures thereof; and
wherein the UV absorbing or barrier agent is selected from the group consisting of benzone compounds, glyceryl PABA, roxadimate, octocrylene, octyl methoxycinnamate, ethoxyethyl p-methoxycinnamate, homomenthyl salicylate, ethylhexyl salicylate, trolamine salicylate, ecamsule, ensulizole, bemotrizinol, bisoctrizole, zinc oxide, titanium dioxide, and mixtures thereof.
11. A method to treat a skin disorder or rejuvenate the skin in a human in need thereof consisting essentially of topically administering to the human the topical emulsion of claim 1.
12. The method of claim 11, wherein the skin disorder is selected from the group consisting of eczema, psoriasis, dermatitis, itching dermatosis, rosacea, perioral dermatitis, acne, and melanoma.
13. The method of claim 11, wherein the condition of the human's skin is selected from the group consisting of pruritus, dryness, skin rash, redness, swelling of the skin, itching, crusting, flaking, blistering, cracking, oozing, and bleeding.
14. The method of claim 12, wherein the dermatitis is selected from the group consisting of atopic dermatitis, contact dermatitis, xerotic eczema, and seborrheic dermatitis.
15. The method of claim 11, wherein the topical emulsion is administered to the human in an amount between about 100 nmol to about 1 micro mol/cm2.
US16/455,002 2018-06-29 2019-06-27 Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care Active US10864189B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US16/455,002 US10864189B2 (en) 2018-06-29 2019-06-27 Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862692178P 2018-06-29 2018-06-29
US16/455,002 US10864189B2 (en) 2018-06-29 2019-06-27 Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care

Publications (2)

Publication Number Publication Date
US20200000765A1 US20200000765A1 (en) 2020-01-02
US10864189B2 true US10864189B2 (en) 2020-12-15

Family

ID=69054881

Family Applications (1)

Application Number Title Priority Date Filing Date
US16/455,002 Active US10864189B2 (en) 2018-06-29 2019-06-27 Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care

Country Status (1)

Country Link
US (1) US10864189B2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022232824A1 (en) * 2021-04-28 2022-11-03 Demetrix, Inc. Use of cannabinoids in the treatment of inflammation and aging in the skin
US11524040B2 (en) 2020-08-24 2022-12-13 Charlotte's Web, Inc. Composition for the treatment of acne
EP4268799A1 (en) 2022-04-01 2023-11-01 TF Holdings LLC Skin treatment composition containing cannabinoids
EP4316474A1 (en) 2022-08-02 2024-02-07 TF Holdings LLC Wound treatment topical composition containing cannabinoids
US12016829B2 (en) 2021-04-08 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020260090C9 (en) * 2019-04-15 2023-08-31 Metagenics LLC Novel hemp and PEA formulation and its use
US11273122B2 (en) * 2020-02-11 2022-03-15 Therese Mainella Combination of cannabis, derivatives thereof and additives in oral care compositions
WO2022098366A1 (en) * 2020-11-09 2022-05-12 Redwood Ip Holding, Llc Skincare compositions for preventing transepidermal water loss

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160101063A1 (en) * 2013-05-02 2016-04-14 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160101063A1 (en) * 2013-05-02 2016-04-14 Mor Research Applications Ltd. Cannabidiol for the prevention and treatment of graft-versus-host disease

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11524040B2 (en) 2020-08-24 2022-12-13 Charlotte's Web, Inc. Composition for the treatment of acne
US12016829B2 (en) 2021-04-08 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
WO2022232824A1 (en) * 2021-04-28 2022-11-03 Demetrix, Inc. Use of cannabinoids in the treatment of inflammation and aging in the skin
EP4268799A1 (en) 2022-04-01 2023-11-01 TF Holdings LLC Skin treatment composition containing cannabinoids
EP4316474A1 (en) 2022-08-02 2024-02-07 TF Holdings LLC Wound treatment topical composition containing cannabinoids

Also Published As

Publication number Publication date
US20200000765A1 (en) 2020-01-02

Similar Documents

Publication Publication Date Title
US20180021247A1 (en) Topical compositions comprising hydroxy acids and cannabinoids for skin care
US10864189B2 (en) Topical compositions comprising polyolprepolymers, stem cell, and cannabinoids for skin care
US5962526A (en) Pharmaceutical compositions containing hydroxycarboxylic acids and/or ketocarboxylic acids and methods of using same
US5665776A (en) Additives enhancing topical actions of therapeutic agents
US5877212A (en) Molecular complex and control-release of alpha hydroxyacids
US20040214215A1 (en) Bioavailability and improved delivery of alkaline pharmaceutical drugs
JPH05139947A (en) Composition containing 2-hydroxycarboxylic acid and related compound and method for relieving symptoms of dermotological aging
JP2003503436A (en) Oligosaccharide aldonic acids and their topical use
AU2003220691A1 (en) Urea compositions
US20090232755A1 (en) Combination therapies for treating photodamaged skin
US20060269495A1 (en) Alpha hydroxy acid compositions
CN113924108B (en) Topical skin care compositions comprising centella asiatica
US6573301B1 (en) Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
US9956163B2 (en) Formulations for lightening skin and treating hyperpigmentation
KR20210008327A (en) Anti-aging and skin tone whitening composition and method therefor
WO2005027977A2 (en) Diclofenac compositions for the treatment of skin disorders
JP2000186036A (en) Chemical peeling agent composition
US20040170659A1 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
JP2007332078A (en) Agent for external use containing ozone-dissolved glycerol solution such as cosmetic, quasi-drug or medicament (pharmaceutical)
AU2010247394B8 (en) Use of delta-tocopheryl-carbohydrate as a depigmenting agent
JP2009001575A (en) Agent for external use containing ozone-dissolved glycerol solution such as cosmetic, quasi-drug or medicament (pharmaceutical)
KR101459134B1 (en) Cosmetic composition containing piceatannol and vitamin A (retinoids)
JP3022541B1 (en) External preparation
CA3181110A1 (en) An antimicrobial composition for tackling malodour
KR101661694B1 (en) Low irritating composition for skin whitening comprising hydroquinone

Legal Events

Date Code Title Description
FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: BIG.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

FEPP Fee payment procedure

Free format text: ENTITY STATUS SET TO SMALL (ORIGINAL EVENT CODE: SMAL); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

STPP Information on status: patent application and granting procedure in general

Free format text: APPLICATION DISPATCHED FROM PREEXAM, NOT YET DOCKETED

STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

STPP Information on status: patent application and granting procedure in general

Free format text: NOTICE OF ALLOWANCE MAILED -- APPLICATION RECEIVED IN OFFICE OF PUBLICATIONS

STPP Information on status: patent application and granting procedure in general

Free format text: PUBLICATIONS -- ISSUE FEE PAYMENT VERIFIED

STCF Information on status: patent grant

Free format text: PATENTED CASE

MAFP Maintenance fee payment

Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY

Year of fee payment: 4